Published in final edited form as:

Pediatr Blood Cancer. 2017 August ; 64(8): . doi:10.1002/pbc.26432.

Management of Adrenal Masses in Patients with Beckwith-Wiedemann Syndrome

Suzanne P. MacFarland¹, Sogol Mostoufi-Moab^{1,2}, Kristin Zelley¹, Peter A. Mattei^{2,3}, Lisa J. States⁴, Tricia R. Bhatti^{2,5}, Kelly A. Duffy⁶, Garrett M. Brodeur^{1,2}, and Jennifer M. Kalish^{2,6}

¹Division of Oncology, the Children's Hospital of Philadelphia, Philadelphia, PA 19104

²Department of Pediatrics, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104

³Department of General, Thoracic, and Fetal Surgery, the Children's Hospital of Philadelphia, Philadelphia, PA 19104

⁴Department of Radiology, the Children's Hospital of Philadelphia, Philadelphia, PA 19104

⁵Department of Pathology and Laboratory Medicine, the Children's Hospital of Philadelphia, Philadelphia, PA 19104

⁶Division of Human Genetics, the Children's Hospital of Philadelphia, Philadelphia, PA 19104

Abstract

Beckwith-Wiedemann syndrome (BWS) is a genetic overgrowth and cancer predisposition syndrome, associated with both benign and malignant adrenal findings. Literature review and an institutional case series elucidate the wide spectrum of adrenal findings in BWS patients. The altered expression of the 11p15 region is likely related to adrenal gland hyperplasia and growth dysregulation. Given the absence of guidelines for managing adrenal findings in BWS, we propose a systematic approach to adrenal findings in BWS patients, to allow for maximum detection of potentially malignant pathology without posing additional risk to patients.

Keywords

Beckwith-Wiedemann syndrome; 11p overgrowth; isolated hemihypertrophy; cancer predisposition; adrenal mass; adrenal cytomegaly; tumor screening

Introduction

Beckwith-Wiedemann syndrome (BWS, OMIM #130650) is a genetic overgrowth and cancer predisposition syndrome characterized by hemihypertrophy, macroglossia, macrosomia, organomegaly, hyperinsulinism, omphalocele/umbilical hernia, and distinct

To whom correspondence should be addressed: Jennifer M. Kalish, MD, PhD, Division of Human Genetics, The Children's Hospital of Philadelphia, CTRB Rm. 3028, 3501 Civic Center Blvd., Philadelphia, PA 19104-4302, USA, Tel: 215-590-1278 Fax: 215-425-7499; kalishj@email.chop.edu.

Conflicts of Interest

The authors have no relevant conflicts of interest to disclose.

facial features.¹ Patients with BWS are also at risk for embryonal tumors such as Wilms tumor, hepatoblastoma, and neuroblastoma in the first 8 years of life.^{1–5} BWS is caused by genetic or epigenetic changes on chromosome 11p15, with either specific gene mutations or changes in DNA methylation in imprinting centers, known as imprinting center 1, H19/IGF2:IG-DMR (IC1) and imprinting center 2, KCNQ1OT1:TSS-DMR 2 (IC2), leading to a dysregulation in genes affecting growth.¹ BWS is more generally classified as the 11p Overgrowth Spectrum, which includes the spectrum of patients from classic BWS to those with isolated hemihypertrophy (IHH).^{6,7} For the purposes of these recommendations, we will henceforward refer only to BWS, but would recommend these screening guidelines for any patient within the 11p Overgrowth Spectrum, including BWS and IHH.

The overall risk of intra-abdominal tumor development in BWS is somewhere between 5–10%^{2–5} Patients with BWS are screened with serial abdominal ultrasounds to evaluate for Wilms tumor and neuroblastoma, and alpha-fetoprotein (AFP) measurements to evaluate for hepatoblastoma, allowing early detection and management of these high-risk malignancies. Adrenocortical carcinoma is the next most common tumor type reported; additionally, other malignant and non-malignant adrenal masses are reported.⁴ Given this frequency, a consistent approach for evaluating adrenal masses in BWS is warranted.

Recommendations for following an incidentally noted adrenal mass have been developed for otherwise normal patients,⁸ but there are no recommendations for adrenal evaluation in patients with BWS. These patients have an increased risk of malignancy, and this must be considered and weighed against the risk of further diagnostic evaluation with biopsy or resection. The objective of this study is to review the adrenal findings in a large number of BWS patients evaluated at a BWS referral center, propose a potential underlying mechanism for the higher incidence of adrenal findings, and delineate steps for the evaluation of an adrenal mass detected during surveillance screening.

Methods

We conducted a literature review most recently updated in September 2016 via PubMed and the Cochrane Library for case reports and series involving patients with BWS and adrenal findings. These were compiled and analyzed for inclusion, based on their relevance to the subject matter included in this review.

Our institutional database of patients with BWS (Children's Hospital of Philadelphia, IRB #13-010658) was reviewed for patients with adrenal findings. Evaluation and clinical decisions for these patients were made in accordance with currently available literature regarding adrenal mass management in pediatric patients. Age subdivision and size classification were based on the Children's Oncology Group (COG) guidelines for management of infants with adrenal masses concerning for neuroblastoma.⁹ Additionally, a comprehensive literature review was conducted to review both any available guidelines for management of incidentally noted adrenal masses in adults, as well as prior studies of expectant management of infantile neuroblastoma detected by mass screening in Japan.^{8,10} Guidelines were established using this available literature and institutional experience with BWS.

Results

Literature review reveals a significant variation in the type of adrenal mass detected in BWS (Table 1).^{11–36} We subcategorized these masses into the three most commonly reported adrenal findings: adrenal hyperplasia and cysts, adrenal adenoma, neuroendocrine tumors; and also report other masses and tumors such as adrenal calcification and adrenal carcinoma. As previously noted, the risk of tumor development in BWS is highest in the first 8 years of life, and the majority of adrenal masses are also uncovered within this time frame. Although a genetic subtype of BWS was not available for all patients included in our literature review, the majority had hemihypertrophy, and those patients without clear hemihypertrophy had other clear indicators of BWS (Table 1). The majority were uncovered on screening ultrasound, often in the perinatal period. In each case, follow-up was dependent upon institutional standards or best practice. However, no clear criteria for evaluation and follow-up of adrenal masses in these patients has been proposed.

The case series from our institution is included in the Supplemental Table 1, and included nine patients with genetically confirmed BWS and an adrenal mass. Each adrenal mass in our series was picked up on imaging. Mass type varied and included four patients with adrenal hemorrhage (one bilateral), two patients with an adrenal adenoma, one patient with neuroblastoma, one patient with bilateral pheochromocytoma, and one patient with adrenal hyperplasia. Follow-up was based on the algorithm to be presented in the following section.

Discussion

The literature review and our institutional findings demonstrate significant diversity in adrenal findings in BWS patients. As these patients are predisposed to multiple cancer types, including adrenocortical carcinoma, it is important to appropriately screen and treat these patients when masses are uncovered on routine screening. In the following sections, we propose a system for evaluation of patients with BWS and adrenal findings based on the increased risk of malignancy in these patients.

Underlying physiology of adrenal findings in BWS

There are several genetic changes that lead to the BWS phenotypic spectrum, most important of which are up-regulation of insulin-like growth factor 2 (*IGF2*) and down-regulation of *H19* and cyclin-dependent kinase inhibitor 1C (*CDKN1C*); all three genes are major growth regulators in early development. IC1 gain of methylation on the maternal chromosome leads to increased expression of *IGF2* and decreased expression of *H19*; alternately, hypomethylation of IC2 leads to a decrease in *CDKN1C* expression.^{1,37} Both changes occur in paternal uniparental disomy (pUPD11).^{1,37} Hereditary causes of BWS are responsible for 10–15% of cases, most commonly involving mutations in *CDKN1C* and less frequently involving one or both of the 11p15 imprinting centers, leading to aberrant 11p15 methylation.³⁸ These alterations in expression of *IGF2* and *CDKN1C* can lead to deviations in fetal adrenal development.

Development of the fetal adrenal gland is a complex and highly-regulated process, and *IGF2* is a major modulator in fetal adrenal growth and steroidogenesis.^{39,40} In two large

sequencing projects evaluating pediatric patients with adrenocortical tumors, *IGF2* was overexpressed (with 11p loss of heterozygosity) in the majority of tumors.^{41,42} *IGF2* overexpression promotes adrenocortical carcinoma, but its expression alone is not sufficient for adrenal carcinogenesis.⁴³ Thus, an increase in *IGF2* expression seen in BWS could similarly affect fetal adrenal development.

Alterations in *CDKN1C* expression have also been tied to changes in adrenal growth and development. In a *Cdkn1c* knockdown mouse model, adrenal cell hyperplasia was noted, most notably in the adrenal cortex.⁴⁴ Alternatively, patients with gain of function *CDKN1C* mutations are phenotypically growth restricted, and in particular have adrenal hypoplasia.³⁸

Therefore, *IGF2* over-expression and *CDKN1C* downregulation in patients with BWS is a plausible explanation for adrenal cortex hypertrophy, as well as predisposition to adrenocortical malignancy. In our case series, epigenetic changes leading to dysregulated *IGF2* expression was present in 78% (7/9) of patients with adrenal findings, and the other two patients had IC2 loss of methylation and decreased *CDKN1C* expression (Supplemental Table S1). Based on previous research showing that these aberrations lead to abnormal fetal adrenal development and potentially predispose to malignancy, this is a plausible explanation for the increased frequency of adrenal findings in BWS. The patients in our institutional case series had a spectrum of adrenal change, from adrenal hemorrhage or adrenal cytomegaly to malignant tumors such as neuroblastoma. Further investigation is necessary for a better understanding of the genetic mechanism leading to adrenal masses in BWS.

Recent studies of BWS patients have shown that the epigenotype influences the phenotypic risk of cancer; yet to date, no molecular subgroup is predictive of risk of adrenocortical tumors.^{3,7,45} It is possible that with further understanding of mechanism, those patients at higher risk of adrenal masses may be identified based on their epigenotype. In the absence of an epigenetic stratification, we propose a method to identify and evaluate patients with BWS at higher risk of adrenal malignancy.

Clinical evaluation of adrenal masses in BWS

As shown in a review of available literature and in our own institutional case series, adrenal findings are common in BWS patients, and require further evaluation given the increased adrenal tumor risk in these patients, as compared to patients without BWS. Our recommended general approach to adrenal findings discovered on routine surveillance screening in patients with BWS is shown in Figure 1. Our goal is to risk stratify patients based on age and clinical features to prevent adverse outcomes without leading to unnecessary imaging or invasive procedures in these patients.

We first evaluate patients for the presence of high-risk features, as defined below, and the nature of the mass (cystic versus solid). In the case of a solid mass without high-risk features, we then stratify patients based on age, as detailed below. Our recommendations are based on the currently available literature for adrenal masses in patients <6 months, as these patients are less likely to have a malignant mass and/or a mass requiring further intervention as compared to those patients ≥ 6 months.^{10,46–49} Of note, we would not include patients

with clear and isolated adrenal hemorrhage (without cystic component or mass) in this treatment schema or ongoing surveillance, as adrenal hemorrhage is present the general population at a similar rate and does not imply any inherent risk of malignancy.⁵⁰

High Risk Features—Regardless of age, patients should be evaluated for the presence of high risk features, which include signs or symptoms of underlying metastatic disease and signs of adrenocortical hormone production. These features are considered high risk because they require a more systemic evaluation and imply that the mass is inherently not benign. Patients should be regularly evaluated via examination and careful history to uncover any underlying symptoms of systemic or metastatic disease. Patients should also be evaluated for any signs of excess adrenocortical hormone, resulting in virilization and hypertension. If these symptoms occur, patients should have further evaluation including full body imaging and adrenocortical hormone levels: random cortisol level, adrenocorticotrophic hormone (ACTH), 17(OH) progesterone, dehydroepiandrosterone sulfate (DHEAS), androstenedione, and testosterone. If an adrenocortical tumor is suspected, it should be fully resected; residual tumor in a patient with an adrenocortical tumor would lead to a worse overall outcome for that patient.

Increasing size of an adrenal mass during the observation period should also raise concern, with the patient requiring closer follow-up evaluations and more regularly scheduled surveillance imaging. A 50% size increase was established by COG in monitoring adrenal masses <6 months of age, and has been effective in risk stratifying patients with high-risk lesions in this population; 5 mm has been used in other observational studies.^{9,48} If the size of the mass increases by 50% during the observation period (2 years after finding or until it is no longer present), the mass should undergo complete resection. If the mass increases by <50%, the patient should have imaging at 3–6 week intervals until the mass size stabilizes (or until the mass is resected).

Cystic Masses—For patients with cystic masses without high-risk features, regardless of age, observation alone with ultrasound imaging every 3 months is adequate, as the majority of these cysts represent an adrenal cyst or hemorrhage. For a mixed cystic/solid mass, we recommend evaluation based on patient age.

Age—Adrenal masses in patients <6 months are less likely to be malignant or require surgical intervention.⁴⁶ Several studies have shown that systematic and close observation in these patients, with careful monitoring parameters, is a safe approach in this age group.^{46,47} Observation of patients with adrenal masses <6 months of age has been shown prospectively by COG to capture all high-risk lesions with 100% survival in this age group, and this is now the standard of care.⁹ We have adopted the COG proposed criteria for expectant observation in adrenal masses <6 months, with some modifications given the increased risk of tumor in patients with BWS.⁴ The majority of these masses are a localized neuroblastoma with favorable outcome, and the remainder are more likely to be benign.⁴⁶ This critical approach allows sparing of surgery in these patients, as surgery poses a higher risk to these patients than localized neuroblastoma.⁹

Less than Six Months—Based on the COG criteria, in a patient <6 months of age with an adrenal mass, observation alone is acceptable if the mass meets certain criteria:^{46,47} for a small, solid adrenal mass (less than or equal to 16 mL volume/3.1 cm diameter) or mixed solid and cystic adrenal mass ≤ 65 mL (if >25% cystic), a first step evaluation includes urine catecholamine metabolites, whole body imaging, and a radiolabeled meta-iodobenzylguanidine (MIBG) scan to evaluate for neuroblastoma and potential metastasis. In patients <6 months, ultrasound can adequately distinguish a cystic adrenal lesion, and thus MRI/CT is not warranted in this age group.⁵¹ If there is evidence of neuroblastoma via either imaging or laboratory studies, the mass should be biopsied and staged.

In a patient with BWS with normal urine catecholamine metabolites and an adrenal mass that lacks MIBG avidity, an adrenocortical tumor should be considered. Although we recommend physical exam for all patients to evaluate for elevated adrenocortical hormones, clinical signs may not be present in all patients. For this reason, we recommend that patients with a small solid/cystic mass should have adrenocortical hormone levels (random cortisol, ACTH, 17(OH) progesterone, DHEAS, androstenedione, and testosterone) checked. A tumor suspected to be an adrenocortical carcinoma should be fully resected without biopsy. Abnormal adrenocortical hormone levels, should they be present, will provide a biomarker after surgical resection. Additionally, for patients with abnormal labs, involvement of endocrinology may be warranted for pre- and post-operative management of the patient.

If the proposed imaging and laboratory studies are reassuring, these patients can be followed with an ultrasound evaluation every 6 weeks for up to 2 years after the initial mass is seen, then transitioned to every 3 months until 8 years of age. The end of surveillance can also be modified if a patient has high-risk features, or a tumor that is at high risk of late recurrence, such as pheochromocytoma. For patients with high-risk features as previously defined, or patients with a mass that is larger than the size cutoff (16 mL or 3.1 cm diameter, or 65 mL if >25% cystic), they should be referred to the pathway for patients ≥ 6 months.

At and Over Six Months—In patients ≥ 6 months of age, solid adrenal masses are more likely to be malignant, and thus these patients require a more thorough evaluation. Additionally, in the case of a BWS patient with an adrenal mass, the increased risk of adrenocortical carcinoma should be considered; the risk of adrenocortical tumor is higher in these patients than in the general population of patients with an adrenal mass, and a biopsy of an adrenocortical carcinoma without proper preparation will increase risk to the patient.

In any BWS patient with an adrenal mass, either solid or mixed solid/cystic, the first step should be further imaging evaluation with an MRI to better delineate the mass and to prepare for a possible surgical approach. After initial imaging, additional evaluation for a neuroblastoma including an MIBG and urine catecholamine metabolites are recommended. If these assessments are consistent with diagnosis of neuroblastoma, biopsy and staging can be completed. If MIBG and urine catecholamine metabolites are negative, an adrenocortical hormone panel including random cortisol, ACTH, 17(OH) progesterone, DHEAS, androstenedione, and testosterone should be sent. This will help in planning a full surgical resection should the mass be considered high risk for adrenocortical carcinoma. Regardless of adrenal cortical hormone panel results, the patient should undergo complete resection of

mass and further staging workup, as adrenocortical tumor or other malignancy remains on the differential, and it is not possible to delineate risk further without pathology.

Conclusions

Adrenal masses are more frequent in patients with BWS than in the general population. Based on our institutional experience with this patient population, we propose an evaluation pathway for these patients in addition to BWS protocols. The proposed evaluation pathway balances the risks of unnecessary testing and procedures, while still ensuring that high-risk adrenal masses are diagnosed and treated appropriately. Additionally, these guidelines more broadly outline the available recommendations for evaluating adrenal masses in the pediatric patient; while they account for the increased risk of adrenal malignancy in the BWS population, a similar schema could be considered for any child with an adrenal mass.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was made possible by the generous funding support of the Alex's Lemonade Stand Foundation (J.M.K.), the National Institutes of Health (K07 CA166177 S.M.M.; K08 CA193915 J.M.K.; T32HD043021-11A1 S.P.M.), and St. Baldrick's Foundation (J.M.K.)

Abbreviations key

BWS	Beckwith-Wiedemann syndrome
IC1	Imprinting center 1
IC2	Imprinting center 2
pUPD11	Paternal uniparental disomy 11
LOH	Loss of heterozygosity
IHH	Isolated hemihypertrophy
AFP	Alpha-fetoprotein
MIBG	Meta-iodobenzylguanidine
IGF2	Insulin-like growth factor 2
CDKN1C	Cyclin-dependent kinase inhibitor 1C
ACTH	Adrenocorticotrophic hormone
DHEAS	Dehydroepiandrosterone sulfate
COG	Children's Oncology Group

References

1. Shuman C, Beckwith B. Beckwith-Wiedemann Syndrome. GeneReviews. 2016; 2000 Last update 11 Aug 2016.
2. Debaun MR, Tucker MA. Risk of cancer during the first four years of life in children from the Beckwith-Wiedemann Syndrome Registry. *The Journal of pediatrics*. 1998; 132(3):398–400. [PubMed: 9544889]
3. Ibrahim A, Kirby G, Hardy C, et al. Methylation analysis and diagnostics of Beckwith-Wiedemann syndrome in 1,000 subjects. *Clinical epigenetics*. 2014; 6(1):11. [PubMed: 24982696]
4. Lapunzina P. Risk of tumorigenesis in overgrowth syndromes: a comprehensive review. *American journal of medical genetics Part C, Seminars in medical genetics*. 2005; 137C(1):53–71.
5. Mussa A, Gerrero GB. Letter to the Editor: Screening in Beckwith-Wiedemann Syndrome: a complex issue. *Journal of Pediatric Hematology and Oncology*. 2015; 37(8):627.
6. Hoyme HE, Seaver LH, Jones KL, Procopio F, Crooks W, Feingold M. Isolated hemihyperplasia (hemihypertrophy): Report of a prospective multicenter study of the incidence of neoplasia and review. *American Journal of Medical Genetics*. 1998; 79:274–278. [PubMed: 9781907]
7. Mussa A, Molinatto C, Baldassarre G, et al. Cancer Risk in Beckwith-Wiedemann Syndrome: A Systematic Review and Meta-Analysis Outlining a Novel (Epi)Genotype Specific Histotype Targeted Screening Protocol. *The Journal of pediatrics*. 2016
8. Thompson GB, Young WF Jr. Adrenal Incidentaloma. *Current Opinion in Oncology*. 2003; 15:84–90. [PubMed: 12490767]
9. Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants. *Annals of surgery*. 2012; 256:573–580. [PubMed: 22964741]
10. Tanaka M, Kigasawa H, Kato K, et al. A prospective study of a long-term follow-up of an observation program for neuroblastoma detected by mass screening. *Pediatric blood & cancer*. 2010; 54(4):573–578. [PubMed: 20049932]
11. Taide D, Bendre P, Redkar R, Hambarde S. Adrenal masses associated with Beckwith Wiedemann syndrome in the newborn. *Afr J Paediatr Surg*. 2010; 7:209–210. [PubMed: 20859035]
12. Teh S, Ong GB. Early presentation of right adrenal mass, hepatoblastoma, and hepatic cavernous hemangioma in Beckwith-Wiedemann Syndrome. *Medical Journal of Malaysia*. 2007; 62(4):345–346. [PubMed: 18551945]
13. Rahmah R, Yong J, Sharifa N, Kuhnle U. Bilateral adrenal cysts in ectopic pancreatic tissue in Beckwith-Wiedemann Syndrome: Is a conservative approach acceptable? *Journal of Pediatric Endocrinology and Metabolism*. 2004; 17:909–912. [PubMed: 15270410]
14. Akata D, Haliloglu M, Ozmen MN, Akhan O. Bilateral cystic adrenal masses in the neonate associated with the incomplete form of Beckwith-Wiedemann Syndrome. *Pediatric radiology*. 1997; 27:1–2. [PubMed: 8995155]
15. Ciftci AO, Salman AB, Tanyel FC, Hicsonmez A. Bilateral multiple adrenal pseudocysts associated with incomplete Beckwith-Wiedemann Syndrome. *Journal of pediatric surgery*. 1997; 32(9):1388–1390. [PubMed: 9314273]
16. McCauley RG, Beckwith J, Elias E, Faerber E, Prewitt L, Berdon W. Benign hemorrhagic adrenocortical macrocysts in Beckwith-Wiedemann Syndrome. *American Journal of Radiology*. 1991; 157:549–552.
17. Merrot T, Walz J, Anastasescu R, Chaumoitre K, D’Ercole C. Prenatally detected cystic adrenal mass associated with Beckwith-Wiedemann syndrome. *Fetal diagnosis and therapy*. 2004; 19(6): 465–469. [PubMed: 15539867]
18. Anoop P, Anjay M. Bilateral benign haemorrhagic adrenal cysts in Beckwith-Wiedemann Syndrome: case report. *East African Medical Journal*. 2004; 81(1):59–60. [PubMed: 15080519]
19. Bertoin F, Letouze E, Grignani P, et al. Genome-wide paternal uniparental disomy as a cause of Beckwith-Wiedemann syndrome associated with recurrent virilizing adrenocortical tumors. *Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme*. 2015; 47(7):497–503. [PubMed: 25365508]

20. Wilson M, Peters G, Bennetts B, et al. The clinical phenotype of mosaicism for genome-wide paternal uniparental disomy: two new reports. *American journal of medical genetics Part A*. 2008; 146A(2):137–148. [PubMed: 18033734]
21. Alsultan A, Lovell MA, Hayes KL, Allshouse MJ, Garrington TP. Simultaneous occurrence of right adrenocortical tumor and left adrenal neuroblastoma in an infant with Beckwith-Wiedemann syndrome. *Pediatric blood & cancer*. 2008; 51(5):695–698. [PubMed: 18668518]
22. Beauloye V, Zain F, Malvaux P, et al. Bilateral asynchronous adrenal adenoma in a girl with an incomplete form of Beckwith-Wiedemann Syndrome. *European Journal of Pediatrics*. 2000; 160(2):142–143.
23. Cardinalli IA, de Oliveira-Filho AG, Mastellaro MJ, Ribeiro RC, Aguiar SS. A unique case of synchronous functional adrenocortical adenoma and myelolipoma within the ectopic adrenal cortex in a child with Beckwith-Wiedemann syndrome. *Pathology, research and practice*. 2012; 208(3):189–194.
24. Mizota M, Tamada I, Hizukuri K, et al. Bilateral asynchronous adrenocortical adenoma in a girl with Beckwith-Wiedemann Syndrome. *Clinical Pediatric Endocrinology*. 2005; 14(1):23–26. [PubMed: 24790306]
25. Schofield P, Nystrom A, Smith J, Spitz L, Grant D, Zapf J. Expression of a high molecular weight form of insulin-like growth factor II in a Beckwith-Wiedemann syndrome associated adrenal adenoma. *Cancer Letters*. 1995; 94:71–77. [PubMed: 7621447]
26. sorrentino S, Conte M, Nozza P, et al. Simultaneous occurrence of pancreatoblastoma and neuroblastoma in a newborn with Beckwith-Wiedemann Syndrome. *Journal of Pediatric Hematology and Oncology*. 2010; 32(5):e207–e209.
27. Baldisserotto M, Peletti AB, Angelo de Araujo M, et al. Beckwith-Wiedemann syndrome and bilateral adrenal pheochromocytoma: sonography and MRI findings. *Pediatric radiology*. 2005; 35(11):1132–1134. [PubMed: 15983774]
28. van den Akker EL, de Krijger RR, de Herder WW, Drop SL. Congenital hemihypertrophy and pheochromocytoma, not a coincidental combination? *European Journal of Pediatrics*. 2002; 161:157–160. [PubMed: 11998914]
29. Bemurat L, Gosse P, Ballanger P, et al. Successful laparoscopic operation of bilateral pheochromocytoma in a patient with Beckwith-Wiedemann syndrome. *Journal of Human Hypertension*. 2002; 16:281–284. [PubMed: 11967723]
30. Carney JA, Ho J, Kitsuda K, Young WF Jr, Stratakis CA. Massive neonatal adrenal enlargement due to cytomegaly, persistence of the transient cortex, and hyperplasia of the permanent cortex: findings in Cushing syndrome associated with hemihypertrophy. *The American journal of surgical pathology*. 2012; 36(10):1452–1463. [PubMed: 22982888]
31. Drut RM, Drut R, Gilbert-Barness E, Sotelo-Avila. Adrenal hyperplastic nodules in Wiedemann-Beckwith Syndrome. *Birth Defects: Original Article Series*. 1993; 29(1):367–372. [PubMed: 8280888]
32. Kim ME, Fallon SC, Lopez ME, Hicks MJ, Brandt ML. Recurrent hemangioendothelioma in a pediatric patient: report and review of the literature. *Journal of pediatric surgery*. 2013; 48(6):1426–1428. [PubMed: 23845642]
33. Wassal EY, Habra MA, Vicens R, Rao P, Elsayes KM. Ovarian thecal metaplasia of the adrenal gland in association with Beckwith-Wiedemann syndrome. *World journal of radiology*. 2014; 6(12):919–923. [PubMed: 25550997]
34. Gocmen R, Basaran C, Karcaaltincaba M, et al. Bilateral hemorrhagic adrenal cysts in an incomplete form of Beckwith-Wiedemann syndrome: MRI and prenatal US findings. *Abdominal imaging*. 2005; 30(6):786–789. [PubMed: 16252142]
35. Hertel N, Carlsen N, Kerndrup G, et al. Late relapse of adrenocortical carcinoma in Beckwith-Wiedemann Syndrome: Clinical, endocrinological and genetic aspects. *Acta Paediatrica*. 2004; 92:439–443.
36. Ichiba Y, Aoyama K. Adrenal calcification in Beckwith-Wiedemann Syndrome. *American Journal of the Disabled Child*. 1977; 131:1296–1297.
37. Kalish JM, Jiang C, Bartolomei MS. Epigenetics and imprinting in human disease. *The International journal of developmental biology*. 2014; 58(2–4):291–298. [PubMed: 25023695]

38. Eggermann T, Binder G, Brioude F, et al. CDKN1C mutations: two sides of the same coin. Trends in molecular medicine. 2014; 20(11):614–622. [PubMed: 25262539]
39. Mesiano S, Katz SL, Lee JY, Jaffe RB. Insulin-like growth factors augment steroid production and expression of steroidogenic enzymes in human fetal adrenal cortical cells: Implications for adrenal androgen regulation. Journal of Clinical Endocrinology and Metabolism. 1997; 82(5):1390–1396. [PubMed: 9141522]
40. Coulter CL. Fetal adrenal development: insight gained from adrenal tumors. Trends Endocrinol Metab. 2005; 16(5):235–242. [PubMed: 15949953]
41. Pinto EM, Chen X, Easton J, et al. Genomic landscape of paediatric adrenocortical tumours. Nature communications. 2015; 6:6302.
42. Letouze E, Rosati R, Komechen H, et al. SNP array profiling of childhood adrenocortical tumors reveals distinct pathways of tumorigenesis and highlights candidate driver genes. The Journal of clinical endocrinology and metabolism. 2012; 97(7):E1284–1293. [PubMed: 22539591]
43. Guillaud-Bataille M, Ragazzon B, de Reynies A, et al. IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. PloS one. 2014; 9(8):e103744. [PubMed: 25089899]
44. Duquesnes N, Callot C, Jeannot P, et al. p57(Kip2) knock-in mouse reveals CDK-independent contribution in the development of Beckwith-Wiedemann syndrome. The Journal of pathology. 2016; 239(3):250–261. [PubMed: 27015986]
45. Maas SM, Vansenne F, Kadouch DJ, et al. Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups. American journal of medical genetics Part A. 2016
46. Sauvat F, Sarnacki S, Brisse H, et al. Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer. 2002; 94(9):2474–2480. [PubMed: 12015773]
47. Cozzi DA, Mele E, Ceccanti S, et al. Long-term follow-up of the “wait and see” approach to localized perinatal adrenal neuroblastoma. World journal of surgery. 2013; 37(2):459–465. [PubMed: 23135423]
48. Arakawa A, Oguma E, Aihara T, et al. Long-term follow-up results of the observation program for neuroblastoma detected at 6-month mass screening. The Journal of pediatrics. 2014; 165(4):855–857. e851. [PubMed: 25091258]
49. Nishio N, Mimaya J, Nara T, et al. Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute. Pediatrics international : official journal of the Japan Pediatric Society. 2006; 48(6):531–535. [PubMed: 17168969]
50. Velaphi S, Perlman J. Neonatal adrenal hemorrhage: Clinical and abdominal sonographic findings. Clinical Pediatrics. 2001; 40(10):545–548. [PubMed: 11681820]
51. Hwang SM, Yoo SY, Kim JH, Jeon TY. Congenital Adrenal Neuroblastoma With and Without Cystic Change: Differentiating Features With an Emphasis on the of Value of Ultrasound. AJR Am J Roentgenol. 2016:1–7.

FIGURE 1.

Adrenal Masses in Beckwith-Wiedemann syndrome. (A) Patients under 6 months; a) concerning features requiring further evaluation during period of observation include: increase in size of mass (if $\geq 50\%$ should undergo resection, if $<50\%$ should have imaging at 3 week intervals until mass no longer growing or resected), increase in urine VMA/HVA (increase $\geq 50\%$ above previous value, assuming values above normal range), virilization, or any clinical concern for metastatic disease; b) concern for metastatic disease without MIBG avidity or elevation in urine catecholamines, should first check adrenocortical hormone levels: Random cortisol, ACTH, 17(OH) progesterone, DHES, testosterone, androstenedione. (B) Patients ≥ 6 months; c) assuming no concerning clinical features, including features of adrenal hormone production (hypertension, hirsutism, virilization) or symptoms of systemic or metastatic disease; d) cortisol, ACTH, 17(OH) progesterone, DHES, testosterone, androstenedione

Table 1

Adrenal Masses in Beckwith-Wiedemann syndrome, Literature Review

						Other BWS Findings					
Category	Adrenal Finding	Sex	Age at diagnosis	Presentation	Hemi-hypertrophy	Macroglossia	Hypoglycemia/hyperinsulinism	Umbilical Hernia/Omphalocele	Reference		
Cysts	adrenal cysts (bilateral, hemorrhagic)	M	prenatal	Prenatal US	X				11		
	adrenal cysts (bilateral)	M	23 days	Screening US	X	X	X		12		
	adrenal cyst	M	birth	Screening US		X		X	13		
	adrenal cysts (bilateral)	M	birth	Palpable masses at birth	X	X	X		14		
	adrenal pseudocysts	M	2 days	Palpable masses at birth	X	X			15		
	adrenal cyst (hemorrhagic)	M	prenatal	Prenatal US	X	X		X	16		
	adrenal cyst (hemorrhagic)	M	prenatal	Prenatal US	X		X		16		
	adrenal cyst	F	birth	Palpable mass at birth	X	X	X		16		
	adrenal cyst (hemorrhagic)	M	birth	Palpable mass at birth	X		X		16		
	adrenal cyst (hemorrhagic)	M	birth	Palpable mass at birth	X				16		
	adrenal cyst (hemorrhagic)	Unk	prenatal	Prenatal US	X				16		
	adrenal cyst	M	prenatal	Prenatal US	X	X			17		
	adrenal cyst (hemorrhagic)	F	birth	Screening US		X	X		18		
	adrenal cysts (bilateral)	F	22 days	Palpable masses at birth	X	X	X	X	19		
	adrenal cysts (bilateral)	F	prenatal	Prenatal US	X	X	X	X	20		
Adenoma	adrenal adenoma (virilizing)	F	15 years	Virilization	X	X	X	X	18		
	adrenal adenoma	F	6 months	Screening US	X	X			21		
	adrenal adenoma (bilateral, virilizing)	F	16 months; 4 years	Virilization		X			22		
	adrenal adenoma (virilizing)	F	17 months	Increased cortisol production	X	X		X	23		
	adrenal adenoma (bilateral, virilizing)	F	6 years; 13 years	Virilization		X		X	24		
	adrenal adenoma	M	5 months	Increased cortisol production	X	X		X	25		
	adrenal adenoma	M	8 months	Screening US	X	X	X		16		
Neuro- endocrine tumor	neuroblastoma	M	2 days	Prenatal US	X	X	X		26		
	pheochromocytoma	F	8 years	Screening US		X	X		20		
	pheochromocytoma (bilateral)	M	6 years	Screening US	X		X	X	27		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

						Other BWS Findings					
Category	Adrenal Finding	Sex	Age at diagnosis	Presentation	Hemi-hypertrophy	Macroglossia	Hypoglycemia/hyperinsulinism	Umbilical Hernia/Omphalocele	Reference		
	neuroblastoma	F	6 months	Screening US	X	X			21		
	pheochromocytoma	F	4 years; 12 years	Headache, hypertension	X	X			28		
	pheochromocytoma (bilateral)	F	20 years	Hypertension, malaise	X		X	X	29		
Adrenal hyperplasia	adrenocortical hyperplasia	F	birth	Cushing/virilization	X				30		
	adrenocortical hyperplasia	F	prenatal	Cushing/virilization	X		X		30		
	adrenal cytomegaly	M	birth	Subclinical Cushing	X				30		
	adrenal cytomegaly	F	post-mortem	AVM leading to heart failure	X				31		
Other	hemangioendothelioma	F	7 months; 18 months	Screening CT abdomen	X				32		
	ovarian thecal metaplasia	F	17 years	Screening US	X				33		
	adrenal hemorrhage (bilateral)	M	prenatal	Screening US	X	X			34		
	adrenal carcinoma	F	4 years; 12 years	Cushing/virilization	X				35		
	adrenal calcifications	F	7 years	Incidental finding	X	X		X	36		
	adrenal calcifications	F	4 years	Incidental finding	X	X		X	36		